TY - JOUR
T1 - Artificial Intelligence in Inflammatory Bowel Disease: Bridging Innovation, Implementation and Impact
AU - Iacucci, Marietta
AU - Santacroce, Giovanni
AU - Maeda, Yasuaru
AU - Majumder, Snehali
AU - Hassan, Cesare
AU - Shung, Dennis
AU - Stidham, Ryan
AU - Bisschops, Raf
AU - Naranjo, Valery
AU - Grisan, Enrico
AU - Ghosh, Subrata
PY - 2025/10/13
Y1 - 2025/10/13
N2 - Artificial intelligence (AI) is rapidly transforming the management landscape of inflammatory bowel disease (IBD). While early applications in endoscopy, digital pathology and cross sectional imaging drew significant attention, next-generation AI systems are now emerging, to enable deeper disease understanding, personalized treatment, and streamlined clinical workflows. These advances encompass the multimodal integration of endoscopic, histological, and molecular data ("Endo-Histo-OMICs"), AI-assisted assessment of the intestinal barrier, wearable-based remote monitoring, and the incorporation of large language models (LLMs) for decision support and patient interaction. This Perspective traces the evolution of AI in IBD from domain-specific tools to foundational platforms supporting data-driven precision medicine. We highlight validated AI applications across diagnosis, monitoring, outcome prediction, and neoplasia surveillance. We also explore the expectations of key stakeholders, including clinicians, patients, regulatory bodies, and industry, and discuss unresolved challenges such as explainability, integration into workflows, reimbursement, and environmental sustainability. By aligning innovation with ethical and clinical priorities, AI holds the potential to redefine IBD care. Its future will be shaped by collaboration, transparency, and responsible implementation, ushering in a new era of personalized, efficient, and equitable care for individuals with IBD.
AB - Artificial intelligence (AI) is rapidly transforming the management landscape of inflammatory bowel disease (IBD). While early applications in endoscopy, digital pathology and cross sectional imaging drew significant attention, next-generation AI systems are now emerging, to enable deeper disease understanding, personalized treatment, and streamlined clinical workflows. These advances encompass the multimodal integration of endoscopic, histological, and molecular data ("Endo-Histo-OMICs"), AI-assisted assessment of the intestinal barrier, wearable-based remote monitoring, and the incorporation of large language models (LLMs) for decision support and patient interaction. This Perspective traces the evolution of AI in IBD from domain-specific tools to foundational platforms supporting data-driven precision medicine. We highlight validated AI applications across diagnosis, monitoring, outcome prediction, and neoplasia surveillance. We also explore the expectations of key stakeholders, including clinicians, patients, regulatory bodies, and industry, and discuss unresolved challenges such as explainability, integration into workflows, reimbursement, and environmental sustainability. By aligning innovation with ethical and clinical priorities, AI holds the potential to redefine IBD care. Its future will be shaped by collaboration, transparency, and responsible implementation, ushering in a new era of personalized, efficient, and equitable care for individuals with IBD.
M3 - Review article
SN - 1759-5045
JO - Nature Reviews Gastroenterology and Hepatology
JF - Nature Reviews Gastroenterology and Hepatology
ER -